This article is more than 5 years old. Information may no longer be current.

Weight but not diabetes showed a link to disease-related mortality in prostate cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

In men treated with combined modality therapy for locally advanced prostate cancer, weight appeared to be associated with a greater risk for disease-related mortality, according to recently published data.

Researchers from various U.S. sites examined the correlation between diabetes and mortality among men with locally advanced prostate cancer.

The researchers used data from Radiation Therapy Oncology Group Protocol 92-02, a randomized trial that included 1,554 men treated with radiation therapy and short-term vs. long-term adjuvant goserelin (Zoladex, AstraZeneca). They used regression and proportional hazard models to assess the relationship between diabetes and mortality, including all-cause, prostate cancer-related and non-prostate cancer-related mortality.

During a median follow-up of 8.1 years, 765 deaths occurred, 210 of which were prostate cancer related. Prevalent diabetes was associated with greater all-cause (HR=1.64; P<.0001) and non-prostate cancer mortality (HR=1.88; P<.0001) in a univariate analysis. However, prevalent diabetes was not associated with prostate cancer mortality.

In a multivariate analysis — after adjusting for age, race, Gleason score, tumor stage, PSA, treatment arm and weight — the researchers reported associations similar to those reported in the univariate analysis: prevalent diabetes was related to greater all-cause mortality (HR=1.77; P<.0001) and non-prostate cancer mortality (HR=2.12; P<.0001). Prevalent diabetes was not associated with greater prostate cancer mortality (HR=0.80; P=.34).

However, prostate cancer mortality was linked to age, tumor stage, Gleason score, weight and treatment arm. After assessing weight as a continuous variable (kilograms), the researchers reported that it was associated with greater prostate cancer mortality (HR=1.01; P=.008).

J Clin Oncol. 2008;26:4333-4339.